Bacteriophage study offers new hope in treating GVHD
Researchers from Japan have identified a bacteriophage-derived enzyme that holds promise for future applications in preventing or treating acute graft-versus-host disease (aGVHD).
Acute GVHD is a medical condition that occurs when donor immune cells attack the recipient’s tissues after an allogeneic hematopoietic stem cell transplantation (allo-HCT).
The pathogenesis of aGVHD is influenced by gut dysbiosis and Enterococcus domination.
The bacteriophage-derived enzyme endolysin is capable of targeting biofilms formed by Enterococcus faecalis, offering new hope for tailored interventions in allo-HCT.
Recent studies have highlighted the significant role of the microbiome in aGVHD, with dysbiosis contributing to its pathogenesis.
Dysbiosis can lead to the emergence of pathogenic commensal bacteria including Enterococcus species, particularly E. faecalis and E. faecium, which are associated with multidrug-resistant infections in allo-HCT patients. However, there is a lack of effective therapies specifically tailored to treat dysbiosis in the context of aGVHD.
Advancing phage therapy
A multidisciplinary team led by Associate Professor Kosuke Fujimoto from Osaka Metropolitan University and The University of Tokyo conducted an in-depth analysis of the intestinal bacteriome of allo-HCT patients.
The study aimed to investigate the prevalence and implications of Enterococcus domination in this specific patient population.
Fujimoto said: “During dysbiosis, some symbiotic commensal bacteria acquire pathogenic characteristics, proliferate, and become directly involved in the onset and progression of the disease. Recognising the specificity of phage therapy and its ability to spare beneficial bacteria from adverse effects, we focused our research on phage-derived lytic enzymes.”
The team initiated their investigation by examining the intestinal microbiome of allo-HCT patients, where they noted a predominance of Enterococcus species, particularly E. faecalis. This was notably associated with acute leukaemia.
Despite being sensitive to several antibiotics, E. faecalis strains possessed cytolysin-associated genes, indicating high virulence. Further exploration through metagenomic analysis revealed the presence of genetic signatures associated with biofilm formation.
Whole-genome sequencing of E. faecalis unveiled the presence of an intriguing bacteriophage-derived enzyme known as endolysin, exhibiting potent antibacterial activity specifically targeting E. faecalis.
They found that endolysin exhibited narrow-spectrum activity against E. faecalis and effectively lysed biofilms. Notably, the endolysin’s lytic activity did not affect other intestinal bacteria species.
“Bacteriophage research is gaining momentum, with advancements in phage therapy paving the way for new treatments. Our discovery of the endolysin enzyme holds promise for future applications in preventing or treating acute GVHD,” said Fujimoto.
Diana Spencer, Senior Digital Content Editor, DDW
